Genomic test can predict resistance to chemotherapy in prostate cancer
177Lu-rhPSMA-10.1 injection shows positive radiation dosimetry results in mCRPC
Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence
FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC
